GYNECOLOGIC CANCER: Edited by Jean A. KlasterskyRole of Poly (ADP-Ribose) Polymerase inhibitors beyond BReast CAncer Gene-mutated ovarian tumours: definition of homologous recombination deficiency?Gourley, Charliea; Miller, Rowan E.b,c; Hollis, Robert L.a; Ledermann, Jonathan A.b,dAuthor Information aNicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Edinburgh Centre, MRC IGMM, University of Edinburgh, Edinburgh bDepartment of Medical Oncology, University College London Hospital cDepartment of Medical Oncology, St Bartholomew's Hospital dCancer Research UK and UCL Cancer Trials Centre, University College London Cancer Institute, London, UK Correspondence to Jonathan A. Ledermann, Cancer Research UK & UCL Cancer Trials Centre, UCL Cancer Institute, 90 Tottenham Court Road, London W1T 4TJ, UK. Tel: +20 7679 9898; fax: +20 7679 9899; e-mail: [email protected] Current Opinion in Oncology: September 2020 - Volume 32 - Issue 5 - p 442-450 doi: 10.1097/CCO.0000000000000660 Buy Metrics Abstract Purpose of review PARP inhibitors have transformed the management of BRCA mutant (BRCAmut) high-grade serous and endometroid ovarian cancer (HGOC). However, it is clear that the benefit can be extended beyond this subgroup, particularly to those cancers with homologous recombination repair deficiency (HRD). We review emerging molecular and clinical data to support the use of PARP inhibitors in HRD HGOC and discuss the advantages and disadvantages of different HRD assays. Recent findings Several phase 3 trials support the use of PARP inhibitor maintenance therapy beyond those patients with BRCAmut in the first-line and platinum-sensitive relapse setting. Many of these studies included HRD testing and it is clear, regardless of the assay used, that an incremental reduction in benefit is observed from BRCAmut tumours to HRD to homologous recombination proficient tumours. However, although currently available HRD assays predict the magnitude of benefit from PARP inhibitors, they consistently fail to identify a subgroup of patients who do not benefit. Summary Clinical data support the use of PARP inhibitor maintenance therapy beyond BRCAmut patients. Current HRD tests lack negative predictive value and more research is required to develop a composite HRD assay that provides a dynamic readout of HRD status. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.